ArticleCureus2026
First Case of Mixed Poorly Differentiated Mucinous Adenocarcinoma and High-Grade Neuroendocrine Neoplasm With Amphicrine Differentiation.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amphicrine carcinoma is a rare gastrointestinal carcinoma characterized by dual exocrine and neuroendocrine differentiation within individual tumor cells. Its rarity, overlapping morphological features with those of conventional adenocarcinoma, and evolving classification present diagnostic and therapeutic challenges. We report the rare case of a middle-aged man who presented with dysphagia and weight loss. Imaging revealed a distal esophageal mass, and biopsy confirmed adenocarcinoma. Following neoadjuvant chemoradiation, persistent disease led to esophagogastrectomy. Microscopic examination demonstrated extracellular mucin pools and glandular/cribriform structures, with co-expression of neuroendocrine markers (INSM1, synaptophysin, and chromogranin) and mucin within the same tumor cells. Electron microscopy confirmed the presence of dense-core neurosecretory granules, mucin droplets, and microvilli in the same tumor cells, supporting the diagnosis of amphicrine carcinoma. Amphicrine carcinoma is distinct from conventional adenocarcinoma and mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs), with prognosis determined by histologic grade. Molecular profiling has revealed recurrent copy-number gains on chromosome 20q13.12-q13.2, involving MYT1, NTSR1, and ZBTB46, suggesting a distinct biological profile. Recognition of amphicrine carcinoma is critical for accurate diagnosis, prognostic assessment, and appropriate treatment. Diagnosis relies on careful evaluation of morphologic features and immunohistochemical findings, while histologic grade appears to predict prognosis. Awareness of this rare entity is essential for appropriate clinical management, and further studies are needed to better define its molecular characteristics and guide the development of targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.